Last reviewed · How we verify
ARN-75039
At a glance
| Generic name | ARN-75039 |
|---|---|
| Sponsor | Arisan Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ARN-75039 Lassa Fever Treatment in West Africa (PHASE2)
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (PHASE1)
- A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |